

Stéphane Verguet

PROFESSIONAL ADDRESS Department of Global Health and Population
Harvard T.H. Chan School of Public Health
665 Huntington Avenue, Building 1, Room 1206D
Boston MA 02115, USA
Tel: +1-617-432-1027
Fax: +1-617-432-6733
Email: verguet@hsph.harvard.edu

EDUCATION **University of California, Berkeley, CA, USA**

PhD, Mechanical Engineering 2008

MPP, Goldman School of Public Policy 2008

MS, Mechanical Engineering 2005

Ecole Polytechnique, France

Ingénieur Diplômé de l'Ecole Polytechnique 2003

ACADEMIC APPOINTMENTS **Harvard T.H. Chan School of Public Health, Boston, MA, USA**

Associate Professor of Global Health 2021-

Assistant Professor of Global Health 2015-2021

University of Washington, Seattle, WA, USA

Department of Global Health

Assistant Professor 2014-2015

Acting Assistant Professor 2012-2014

Senior Fellow 2011-2012

Institute for Health Metrics and Evaluation

Post-Graduate Fellow 2009-2011

MAJOR VISITING APPOINTMENTS **Sciences Po, Institut d'Etudes Politiques de Paris, France**

Visiting Professor 2014

MAJOR RESEARCH INTERESTS Priority setting and decision science
Health economics, cost-effectiveness analysis, cost-benefit analysis
Equity, poverty, financial risk protection
Health systems performance

Peer-reviewed publications

1. Szeri AJ, Park SC, **Verguet S**, Weiss A, Katz DF. A model of transluminal flow of anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. *Physics of Fluids* 2008; 20:083101(10 pages).
2. **Verguet S**, Duan C, Liao A, Berk V, Cate JHD, Majumdar A, Szeri AJ. Mechanisms of liquid-liquid interfaces and mixing enhancement in microscale flows. *Journal of Fluid Mechanics* 2010; 652:207-240.
3. **Verguet S**, Young Holt B, Szeri AJ. Increasing the effectiveness of vaginal microbicides: a biophysical framework to rethink behavioral acceptability. *PLoS ONE* 2010; 5(11):e15501(8 pages).
4. **Verguet S**, Walsh JA. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. *Sexually Transmitted Infections* 2010; 86:212-216.
5. Tasoglu S, Peters JJ, Park SC, **Verguet S**, Katz DF, Szeri AJ. The effects of inhomogeneous boundary dilution on the coating flow of an anti-HIV microbicide vehicle. *Physics of Fluids* 2011; 23:93101-093101-9.
6. Delva W, **Verguet S**, Hargrove JW, Williams BG, Sheneberger R, Stander T, Welter A. Treatment-centred prevention: an integrated biomedical and social approach to HIV prevention. *AIDS* 2011; 25(11):1435-1437.
7. **Verguet S** (co-primary author), Stalcup M. Global health and the demands of the day. *Health, Culture and Society* 2011; 1(1):30-44.
8. **Verguet S**, Jassat W, Hedberg C, Tollman S, Jamison DT, Hofman KJ. Measles control in sub-Saharan Africa: South Africa as a case study. *Vaccine* 2012; 30(9):1594-1560.
9. Stalcup M, **Verguet S**. Mothers and children: designing research toward integrated care for both. *Health, Culture and Society* 2012; 3(1):160-171.
10. Johri M, Sharma JK, Jit M, **Verguet S**. Use of measles supplemental immunization activities (SIAs) as a delivery platform for other maternal and child health interventions: opportunities and challenges. *Vaccine* 2013; 9(18):1259-1263.
11. **Verguet S**, Jassat W, Bertram M, Tollman S, Murray CJL, Jamison DT, Hofman KJ. Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform. *Global Health Action* 2013; 6:20056(7 pages).
12. **Verguet S**. Efficient and equitable HIV prevention: a case study of male circumcision in South Africa. *Cost Effectiveness and Resource Allocation* 2013; 11:1.
13. **Verguet S**, Jamison DT. Performance in rate of decline of adult mortality in the OECD, 1970-2010. *Health Policy* 2013; 109(2):137-142.
14. **Verguet S**, Lim SS, Murray CJL, Gakidou E, Salomon JA. Incorporating loss to follow-up in estimates of survival among HIV-infected individuals in sub-Saharan Africa enrolled in antiretroviral therapy programs. *Journal of Infectious Diseases* 2013; 207(1):72-79.

15. **Verguet S** (co-primary author), Kern E, Yuhus K, Odhiambo FT, Kahn JG, Walson JL. Provision of bednets and water filters to delay HIV-1 progression: cost-effectiveness analysis of a Kenyan multi-site study. *Tropical Medicine and International Health* 2013; 18(8):916-924.
16. **Verguet S**, Jamison DT. Improving life expectancy: how many years behind has the USA fallen? A cross-national comparison among high-income countries from 1958 to 2007. *BMJ Open* 2013; 3:e002814(9 pages).
17. **Verguet S**, Stalcup M, Walsh JA. Where to deploy Pre-Exposure prophylaxis in sub-Saharan Africa? *Sexually Transmitted Infections* 2013; 89:628-634.
18. **Verguet S**, Jassat W, Bertram M, Tollman S, Murray CJL, Jamison DT, Hofman KJ. Impact of supplemental immunization activities (SIAs) on health systems: findings from South Africa. *Journal of Epidemiology and Community Health* 2013; 67:947-952.
19. **Verguet S**, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. *Vaccine* 2013; 31(42):4902-4910.
20. Marseille E, Jiwani A, Raut A, **Verguet S**, Walson JL, Kahn JG. Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries. *BMJ Open* 2014; 4:e003987(16 pages).
21. Jiwani A, Matheson A, Kahn JG, Garg N, Raut A, **Verguet S**, Marseille E, Walson JL. Integrated disease prevention campaigns: assessing country opportunity for implementation. *BMJ Open* 2014; 4:e004308(11 pages).
22. **Verguet S**, Jamison DT. Estimates of performance in the rate of decline of under-five mortality for 113 low- and middle-income countries, 1970-2010. *Health Policy and Planning* 2014; 29(2):151-163.
23. **Verguet S**, Laxminarayan R, Jamison DT. Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. *Health Economics* 2015; 24(3):318-332.
24. Norheim OF, Jha P, Hum R, Mathers C, Admasu KB, Woldemariam AT, Sepulveda J, Suraweera W, Pan H, **Verguet S**, Yamey G, Kruk M, Godal T, Jamison DT, Peto R. Avoiding 40% of the premature deaths in each country, 2010-30: review of national mortality trends to help quantify the UN Sustainable Development Goal for health. *Lancet* 2015; 385:239-252.
25. **Verguet S**, Norheim OF, Olson ZD, Yamey G, Jamison DT. Performance in reducing child, maternal, HIV and tuberculosis mortality rates across 109 low- and middle-income countries from 1990-2013. *Lancet Global Health* 2014; 2:e698-709.
26. **Verguet S**, Johri M, Morris S, Gauvreau C, Jha P, Jit M. Controlling measles using supplemental immunization activities: a mathematical model to inform optimal policy. *Vaccine* 2015; 33:1291-1296.
27. Watkins DA, Olson ZD, Murphy S, **Verguet S**, Jamison DT, Nugent RA. Cardiovascular disease and impoverishment averted due to a salt reduction policy in South Africa: an extended cost-effectiveness analysis. *Health Policy and Planning* 2016; 31(1):75-82.

28. Levin CE, Sharma M, Olson ZD, **Verguet S**, Jamison DT, Kim J. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. *Vaccine* 2015; 33:2830-2841.
29. Meara J, Leather AJ, Hagander L, Alkire BC, Bickler SW, Alonso N, Ameh EA, Conteh L, Dare AJ, Rodas E, Mkandawire N, El-Hlabi S, Green RL, **Verguet S**, Derivois Merisier E, Sullivan R, Yamey G, Lavy C, Weiser TG, Rose J, Kamara TB, Wilson IH, Shrimme MG, Grimes CE, Lundeg G, Gillies R, Farmer PE, Raykar NP, Riesel JN, Yip W, Greenberg SL, Roy N, Ismail EA, Davies J, Gawande A. Global surgery 2030: evidence and solutions for achieving health, welfare, and economic development. *Lancet* 2015; 386:569-624.
30. Mock CN, Donkor P, Gawande A, Jamison DT, Kruk ME, Debas HT. As part of the **DGP3 Essential Surgery Author Group**. Essential surgery: key messages from *Disease Control Priorities*, 3rd edition. *Lancet* 2015; 385:2209-2219.
31. **Verguet S**, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, Levin CE, Nugent RA, Pecenka C, Shrimme MG, Memirie ST, Watkins DA, Jamison DT. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. *Lancet Global Health* 2015; 3:e288-296.
32. **Verguet S**, Gauvreau C, Mishra S, MacLennan M, Murphy S, Brouwer E, Nugent RA, Zhao K, Jha P, Jamison DT. The consequences of tobacco taxation on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis. *Lancet Global Health* 2015; 3:e206-216.
33. Hum RJ, **Verguet S**, Cheng Y-L, McGahan A, Cheng Y-L, Jha P. Are global and regional improvements in life expectancy and in child, adult and senior survival slowing? *PLoS ONE* 2015; 10(5):e0124479(14 pages).
34. **Verguet S**, Alkire BC, Bickler SW, Lauer JA, Uribe-Leitz T, Molina G, Weiser TG, Yamey G, Shrimme MG. Modeling the timing and cost of scaling up surgical services in low- and middle-income countries from 2012 to 2030. *Lancet Global Health* 2015; 3:S28-37.
35. Pecenka C, Johansson KA, Memirie ST, Jamison DT, **Verguet S**. Health gains and financial risk protection in Ethiopia: assessing the benefits of diarrhea treatment and prevention. *BMJ Open* 2015; 5:e006402(8 pages).
36. **Verguet S**, Kahn JG, Marseille E, Jiwani A, Kern E, Walson JL. Cost savings associated with the use of long-lasting insecticide-treated bednets and water filters to delay HIV disease progression in Kenya. *Global Health Action* 2015; 8:27695(8 pages).
37. Driessen JR, Olson ZD, Jamison DT, **Verguet S**. Comparing the health and social protection effects of measles vaccination strategies in Ethiopia: an extended cost-effectiveness analysis. *Social Science and Medicine* 2015; 139:115-122.
38. Uribe-Leitz T, Esquivel MM, Molina G, Lipsitz SR, **Verguet S**, Rose J, Bickler S, Gawande AA, Haynes AB, Weiser TG. Projections for achieving the Lancet Commission recommended surgical rate of 5000 operations per 100,000 population by region-specific surgical rate estimates. *World Journal of Surgery* 2015; 39(9):2168-2172.

39. Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, et al. As part of the **DCP3 MNS Author Group**. Addressing the burden of mental, neurological, and substance use disorders: key messages from *Disease Control Priorities*, 3rd edition. *Lancet* 2015; 387:1672-1685.
40. Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, et al. As part of the **DCP3 Cancer Author Group**. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from *Disease Control Priorities*, 3rd edition. *Lancet* 2016; 387:2133-2144.
41. Johansson KA, Pecenka C, Tessema Memirie S, Jamison DT, **Verguet S**. Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: results from an extended cost-effectiveness analysis. *PLoS ONE* 2015; 10(12):e0142691(16 pages).
42. Shrimpe MG, **Verguet S**, Johansson KA, Jamison DT, Kruk ME. Task-shifting, universal public finance, or both for the expansion of surgical access in rural Ethiopia: an extended cost-effectiveness analysis. *Health Policy and Planning* 2016; 31(6):706-716.
43. Olson ZD, Staples J, Mock C, Phuong Nguyen N, Bachani AM, Nugent RA, **Verguet S**. Helmet regulation in Vietnam: impact on health, equity and medical impoverishment. *Injury Prevention* 2016; 22:233-238.
44. Memirie ST, **Verguet S**, Norheim OF, Levin CE, Johansson KA. Inequalities in utilization of maternal and child health services in Ethiopia: the role of primary health care. *BMC Health Services Research* 2016; 16:51.
45. Black RE, Levin, Walker N, Chou D, Liu L, Temmerman M, for the **DCP3 RMNCH Authors Group**. Reproductive, maternal, newborn and child health: key messages from *Disease Control Priorities* 3rd edition. *Lancet* 2016; 388:2811-2825.
46. **Verguet S**. Defining pathways and tradeoffs toward universal health coverage. *International Journal of Health Policy and Management* 2016; 5(7):445-447.
47. Johri M, **Verguet S**, Morris SK, Sharma JK, Ram U, Gauvreau CL, Jha P, Jit M. Adding interventions to mass measles vaccinations in India. *Bulletin of the World Health Organization* 2016; 94:718-727.
48. **Verguet S**, Kim JJ, Jamison DT. Extended cost-effectiveness analysis for health policy assessment: a tutorial. *Pharmacoeconomics* 2016; 34(9):913-923.
49. Kruk ME, Leslie HH, **Verguet S**, Mbaruku GM, Adanu RMK, Langer A. Quality of basic maternal care functions in health facilities of five African countries: an analysis of national health system surveys. *Lancet Global Health* 2016; 4(11):e845-e855.
50. Loganathan T, Jit M, Hutubessy R, Ng C-W, Lee W-S, **Verguet S**. Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system. *Tropical Medicine and International Health* 2016; 21(11):1458-1467.

51. Tolla MT, Strand K, Memirie ST, Norheim OF, Senkoro K, Guteta S, Ababulgu A, Jerene D, Bertram M, **Verguet S**, Johansson KA. Cost-effectiveness analysis of prevention and treatment of cardiovascular disease in an Ethiopian setting: a country contextualization. *Cost Effectiveness and Resource Allocation* 2016; 14:10.
52. **Verguet S**, Nandi A, Filippi V, Bundy DP. Maternal mortality and impoverishment among rich and poor adolescent girls in India and Niger: a modeling study. *BMJ Open* 2016; 6:e011586.
53. Munshi V, Yamey G, **Verguet S**. Trends in state-level child mortality, maternal mortality, and fertility rates In India. *Health Affairs* 2016; 35:1753-1758.
54. Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Garcia Baena I, Laurence YV, Qiang S, Siroka A, Sweeney S, **Verguet S**, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Feldman MW, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lin H-H, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen S-c, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu C-Y, Boccia D, Chadha VK, Charlabous S, Chin D, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant A, Hippner P, Hosseini M, Lalli M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGH, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive TB control in China, India and South Africa: a combined analysis of nine models. *Lancet Global Health* 2016; 4(11):e816-826.
55. **Verguet S**, Memirie ST, Norheim OF. Assessing illness-related poverty: a breakdown of medical impoverishment by disease in Ethiopia. *BMC Medicine* 2016; 14:164.
56. Salti N, Brouwer ED, **Verguet S**. The health, financial and distributional consequences of increases in tobacco tax among smokers in Lebanon. *Social Science and Medicine* 2016; 170:161-169.
57. Sánchez González L, Rodriguez-Lainz A, O'Halloran A, Rowhani-Rahbar A, Liang JL, Lu P-j, Houck PM, **Verguet S**, Williams W. Factors related with pertussis and tetanus vaccination coverage among foreign-born adults living in the US. *Journal of Community Health* 2017; 42(3):573-582.
58. Memirie ST, Metaferia ZS, Norheim OF, Levin C, **Verguet S**, Johansson KA. Catastrophic health expenditure and impoverishment associated with pneumonia and diarrhea treatment costs in Ethiopia. *BMJ Global Health* 2017; 1:e000166.
59. Cookson R, Mirelman A, Griffin S, Asaria M, Dawkins B, Norheim OF, **Verguet S**, Culyer A. Using cost-effectiveness analysis to address health equity concerns. *Value in Health* 2017; 20:206-212.
60. Shrimpe MG, Alkire BC, Grimes C, Chao T, Poenaru D, **Verguet S**. Cost-effectiveness in global surgery: pearls, pitfalls, and a checklist. *World Journal of Surgery* 2017; 41(6):1401-1413.
61. Lin R-T, Lin C-K, Christiani DC, Kawachi I, Cheng Y, **Verguet S**, Jong S. The impact of the introduction of new recognition criteria for overwork-related cardiovascular and cerebrovascular diseases: a cross-country comparison. *Scientific Reports* 2017; 7(1):167.

62. Tolla MT, Norheim OF, **Verguet S**, Bekele A, Amenu K, Abdisa SG, Johansson KA. Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialized cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study. *BMJ Global Health* 2017; 2:e000280.
63. **Verguet S** (co-primary author), Jones E, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M. Characterizing measles transmission in India: a dynamic modeling study using verbal autopsy data. *BMC Medicine* 2017; 15:151.
64. **Verguet S**, Woldemariam AT, Durrett W, Norheim OF, Kruk ME. Is the Sustainable Development Goal target for financial risk protection in health realistic? *BMJ Global Health* 2017; 2:e000216.
65. **Verguet S**, Tarr G, Gauvreau CL, Mishra S, Jha P, Yue C, Qiu S, Liu L, Zhao K. Distributional benefits of tobacco tax and smoke-free workplaces in China: a modeling study. *Journal of Global Health* 2017; 7(2):020701.
66. **Verguet S**, Riumallo-Herl C, Gomez G, Menzies NA, Houben RMGJ, Sumner T, Lalli M, White R, Salomon JA, Cohen T, Foster N, Chatterjee S, Sweeney S, Garcia Baena I, Lonnroth K, Weil DE, Vassall A. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. *Lancet Global Health* 2017; 5(11):e1123-e1132.
67. Chang A, Ogbuaji O, Atun R, **Verguet S**. Dynamic modeling approaches to characterize the functioning of health systems: a systematic review of the literature. *Social Science and Medicine* 2017; 194:160-167.
68. Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P, Armstrong R, Asada Y, Bærøe K, Baird S, Bhutta ZA, Boyer Y, Cuervo LG, Edwards S, Gough D, Greer-Smith R, Grimshaw JM, Johansson KA, Kisia CN, Kristjansson E, Loder E Lyddiatt A, Mbuagbaw L, McGowan J, Moher D, Pantoja T, Petkovic J, Petticrew M, Pottie K, Robberstad B, Shea B, Taljaard M, **Verguet S**, Volmink J, Weijer C, Wells GA, Wester G, White H, Whitehead M, Yoganathan M. Better reporting of health equity in randomised trials: CONSORT-Equity 2017 extension and elaboration. *BMJ* 2017; 359:j5085.
69. Knaul FM, Farmer PE, Krakauer EL, De Lima L, Bhadelia A, Kwete XJ, Arreola-Ornelas H, Gómez-Dantés O, Rodriguez NM, Alleyne G, Connor SR, Hunter DJ, Lohman D, Radbruch L, del Rocío Sáenz Madrigal M, Abu-Saad Huijjer H, Binagwaho A, Bosnjak SM, Clark D, Cleary J, Cossío Díaz JR, Goh C, Goldschmidt-Clermont PJ, Gospodarowicz M, Gwyther L, Higginson IJ, Hughes-Hallett T, Luyirika E, Medina Mora ME, Mwangi-Powell F, Nishtar S, O'Brien ME, Reddy SK, Salerno JA, **Verguet S**, Bhadelia N, Ntuzimira CR, Jimenez J, Perez Cruz PE, Allende S, Spence D, Salas Herrera I, Steedman M, Calderon M, Fan VY, Mendez O, Downing J, Lorenz K, Nugent R, Zimmermann C, Elsner M, Thanh Khanh Q, Paudel BD, Wroe EB, Atun R, Foley KM, Frenk J, Jamison DT, Rajagopal MR. Alleviating the access abyss in palliative care and pain relief: an imperative of universal health coverage. *Lancet* 2018; 391:1391-1454.
70. Prabhakaran D, Anand S, Watkins D, Gaziano T, Wu Y, Mbanya J-C, Nugent R, as part of the **DGP3 Cardiovascular, respiratory, and related disorders Author Group**. Cardiovascular, respiratory, and related disorders: key messages and essential interventions to address their burden in low- and middle-income countries. *Lancet* 2018; 391:1224-1236.

71. Jamison DT, Alwan A, Mock CN, Nugent R, Watkins D, Adeyi O, Alleyne G, Anand S, Atun R, Bertozzi S, Bhutta Z, Binagwaho A, Black R, Blecher M, Bloom BR, Brouwer E, Bundy DAP, Chisholm D, Cullen M, Danforth K, de Silva N, Debas HT, Donkor P, Dua T, Fleming KA, Gallivan M, Garcia P, Gawande A, Gaziano T, Gelband H, Glass R, Glassman A, Gray G, Habte D, Holmes KK, Horton S, Hutton G, Jha P, Kirumira E, Knaul F, Kobusingye O, Krakauer E, Kruk ME, Lachmann P, Laxminarayan R, Levin C, Looi LM, Madhav N, Mahmoud A, Mbanya JC, Measham A, Medina-Mora ME, Medlin C, Mills A, Mills J-A, Moncayo A, Montoya J, Norheim O, Olson Z, Omokhodion F, Oppenheim B, Ord T, Patel V, Patton GC, Peabody J, Prabhakaran D, Qi J, Ruacan S, Sankaranarayanan R, Sepúlveda J, Skolnik R, Smith KR, Soucat A, Temmerman M, Tollman S, **Verguet S**, Walker D, Walker N, Wu Y, Zhao K. Universal health coverage and intersectoral action for Health: lessons from Disease Control Priorities, 3rd Edition. *Lancet* 2018; 391(10125):1108-1120.
72. Bundy DAP, de Silva N, Horton S, Patton GC, Schultz L, Jamison DT, as part of the **DCP3 Child and Adolescent Development Author Group**. Investment in child and adolescent health and development: key messages from Disease Control Priorities, 3rd Edition. *Lancet* 2018; 391:687-699.
73. Portnoy A, Jit M, Helleringer S, **Verguet S**. The impact of measles supplementary immunization activities on opportunities for vaccination and equity in low- and middle-income countries. *Vaccine* 2018; 36(1):170-178.
74. Loganathan T, Ng C-W, Lee W-S, Hutubessy R, **Verguet S**, Jit M. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. *Health Policy and Planning* 2018; 33(2):204-214.
75. Postovolska I, Lavado R, Tarr G, **Verguet S**. Estimating the distributional impact of increasing taxes on tobacco products in Armenia: results from an extended cost-effectiveness analysis. *Health Systems & Reform* 2018; 4(1):30-41.
76. Chang A, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D, Garske T, Jackson M, Jean K, Jit M, Jones E, Suraratdecha S, Bullock O, Johnson H, Brenzel L, **Verguet S**. The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. *Health Affairs* 2018; 37(2):316-324.
77. Memirie ST, Habtemariam MK, Asefa M, Deressa BT, Abayneh G, Tsegaye B, Abraha MW, Ababi G, Jemal A, Rebbeck TR, **Verguet S**. Estimates of cancer incidence in Ethiopia in 2015 using population-based registry data. *Journal of Global Oncology* 2018; 4:1-11.
78. Riumallo-Herl C, Chang A, Brenzel L, Clark S, Constenla D, Clark A, **Verguet S**. Poverty reduction and equity benefits from the introduction or scaling up of measles, rotavirus, and pneumococcal vaccines in low- and middle-income countries: findings from a modeling study. *BMJ Global Health* 2018; 3(2):e000613.
79. Postovolska I, Helleringer S, Kruk ME, **Verguet S**. The impact of measles supplementary immunization activities on utilization of maternal and child health services in low- and middle-income countries. *BMJ Global Health* 2018; 3:e000466.
80. Skaftun EK, **Verguet S**, Norheim OF, Johansson KA. Geographic health inequalities in Norway: a Gini analysis of cross-county differences in mortality from 1980 to 2014. *International Journal for Equity in Health* 2018; 17:64.

81. Khadka A, Perales NA, Wei DJ, Gage AD, Haber N, **Verguet S**, Patenaude B, Fink G. Malaria control across borders: quasi-experimental evidence from the Trans-Kunene Malaria Initiative (TKMI). *Malaria Journal* 2018; 17:224.
82. Chang A, Riumallo-Herl C, Brenzel L, Resch S, Salomon JA, **Verguet S**. Estimating the distribution of morbidity and mortality of childhood diarrhea, measles, and pneumonia by socio-economic group in low- and middle-income countries. *BMC Medicine* 2018; 16:102.
83. De Neve J-W, Andriantavison RL, Croke K, Krisam J, Rajoela VH, Rakotoarivony RA, Rambeloson V, Schultz LB, Qamruddin J, **Verguet S**. Health, financial, and education gains of investing in preventive chemotherapy for schistosomiasis, soil-transmitted helminthiasis, and lymphatic filariasis in Madagascar: a modeling study. *PLoS Neglected Tropical Diseases* 2018; 12(12):e0007002.
84. James E, Saxena A, Franco Restrepo C, Llorente B, Vecino-Ortiz AI, Villar Uribe M, Iunes RF, **Verguet S**. Distributional health and financial benefits of increased tobacco taxes in Colombia: results from a modelling study. *Tobacco Control* 2019; 28:374-380.
85. Hauck K, Morton A, Chalkidou K, Chi Y-L, Culyer A, Levin C, Meacock R, Over M, Thomas R, Vassall A, **Verguet S**, Smith PC. How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations. *Social Science & Medicine* 2019; 220:141-149.
86. Haakenstad A, Coates M, Marx A, Bukhman G, **Verguet S**. Disaggregating catastrophic health expenditure by disease area: cross-country estimates based on the World Health Surveys. *BMC Medicine* 2019; 17:36.
87. Wingfield T, **Verguet S**. Active case finding in tuberculosis-affected households is cost-effective: it's time for scale up. *Lancet Global Health* 2019; 7:e296-298.
88. Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, **Verguet S**. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. *Lancet Global Health* 2019; 7:e472-481.
89. **Verguet S**, Feldhaus I, Jiang Kwete X, Aqil A, Atun A, Bishai D, Cecchini M, Guerra Junior AA, Habtemariam MK, Jbaily A, Karanfil O, Kruk ME, Haneuse S, Norheim OF, PC Smith, Tolla MT, Zewdu S, Bump JBB. Developing Health System Modeling Research to Identify Good Value for Money Investments in Health System Strengthening. *BMJ Global Health* 2019; 4:e001311.
90. Bigelow B, Desalegn D, Salomon JA, **Verguet S**. Modeling hospital operations in a low-income country: a case study of the obstetrics ward at Tikur Anbessa Specialized Hospital, Ethiopia. *BMJ Global Health* 2019; 4:e001281.
91. Memirie ST, Tolla MT, Desalegn D, Hailemariam M, Norheim OF, **Verguet S**, Johansson KA. A Cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia. *Health Policy & Planning* 2019; 34(4):289-297.
92. Saxena A, Stacey N, Del Rey Puech P, Mudara C, Hofman K, **Verguet S**. The distributional impact of sugar-sweetened beverage taxation in South Africa: findings from an extended cost-effectiveness analysis. *BMJ Global Health* 2019; 0:e001317.

93. Lovato Pires de Lemos L, Carvalho de Souza M, Moreira Pena D, Ribeiro Fernandes Almeida PH, Godman B, **Verguet S**, Guerra Junior AA, Leal Cherchiglia M. Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: a systematic review and meta-analysis. *PLoS ONE* 2019; 14(10):e0224012(17 pages).
94. Johansson KA, Tolla MT, Memirie ST, Miljeteig I, Habtemariam MK, Wolde-mariam AT, **Verguet S**, Norheim OF. Country contextualization of cost-effectiveness studies: lessons from Ethiopia. *BMJ Global Health* 2019; 4:e001320(9 pages).
95. Ying R, Fekadu L, Schackman BR, **Verguet S**. Spatial distribution and characteristics of HIV clusters in Ethiopia. *Tropical Medicine and International Health* 2020; 25(3):301-307.
96. Daniels KM, Riesel JN, **Verguet S**. Meara JG, Shrimpe MG. The scale-up of the global surgical workforce: can estimates be achieved by 2030? *World Journal of Surgery* 2020; 44:1053-1061.
97. Fekadu Assebe L, Jiang Kwete X, Wang D, Liu L, Norheim OF, Jbaily A, **Verguet S**, Johansson KA, Tolla MT. Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis. *Malaria Journal* 2020; 19:41(10 pages).
98. De Neve J-W, Harttgen K, **Verguet S**. Nationally and regionally representative analysis of 1.65 million children aged under 5 years using a child-based human development index: A multi-country cross-sectional study. *PLoS Medicine* 2020; 17(3):e1003054(18 pages).
99. Portnoy A, Jit M, Helleringer S, **Verguet S**. Comparative distributional impact of routine immunization and supplementary immunization activities in delivery of measles vaccine in low- and middle-income countries. *Value in Health* 2020; 23(1):891-897.
100. Sando D, Kintu A, Okello S, Kawungezi PC, Guwatudde D, Mutungi G, Muyindike W, Menzies NA, Danaei G, **Verguet S**. Cost-effectiveness analysis of integrating screening and treatment of selected non-communicable disease risk factors into HIV/AIDS treatment in Uganda. *Journal of the International AIDS Society* 2020; 23(S1):e25507(30-41).
101. Kintu A, Sando D, Okello S, Mutungi G, Guwatudde, Menzies NA, Danaei G, **Verguet S**. Integrating care for non-communicable diseases into routine HIV services: key considerations for policy design in sub-Saharan Africa. *Journal of the International AIDS Society* 2020; 23(S1):e25508(12-16).
102. Kiros M, Dessie E, Jbaily A, Tolla MT, Johansson KA, Norheim OF, Memirie ST, **Verguet S**. The burden of household out-of-pocket health expenditures in Ethiopia: estimates from a nationally representative survey (2015-2016). *Health Policy and Planning* 2020; 35(8):1003-1010.
103. Jbaily A, Feldhaus I, Bigelow B, Kamareddine L, Tolla MT, Bouvier M, Kiros M, **Verguet S**. Toward health system strengthening in low- and middle-income countries: insights from mathematical modeling of drug supply chains. *BMC Health Services Research* 2020; 20(1):776(12 pages).

104. Kintu A, Sando D, Guwatudde D, Bahendeka S, Kawungezi PC, Mutungi G, Muyindike W, Menzies N, Okello S, Danaei G, **Verguet S**. Quantifying the burden of cardiovascular diseases among people living with HIV in Uganda: findings from a modeling study. *Journal of Global Health Reports* 2020; 4:e2020076(10 pages).
105. Li Z, Fawzi WW, Cohen JL, Verguet S. Equity and distributional impact on stunting of a nutritional package targeting children aged 6-36 months in China: findings from a modeling study. *Nutrients* 2020; 12(9):2643(16 pages).
106. Bukhman G, Mocumbi AO, Atun R, Becker A, Bhutta Z, Binagwaho A, Clinton C, Coates MM, Dain K, Dalil S, Ezzati M, Gottlieb G, Gupta I, Gupta N, Hyder A, Jain Y, Kruk ME, Makani J, Marx A, Miranda JJ, Norheim OF, Nugent R, Roy N, Stefan DC, Wallis L, Mayosi B, for **The Lancet NCDI Poverty Commission Study Group**. The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion. *Lancet* 2020; 396:991-1044.
107. Bigelow B, **Verguet S**. Characterising the scale-up and performance of antiretroviral therapy programmes in sub-Saharan Africa: an observational study using growth curves. *BMJ Open* 2020; 10:e034973(9 pages).
108. Poole DN, Bärnighausen T, Hedt-Gauthier B, **Verguet S**, Castro MC. Spatial-temporal trends in forced migrant mortality, 2014-2018. *BMJ Global Health* 2020; 5:e002885(6 pages).
109. Blanchet K, Alwan A, Antoine C, Cros MJ, Feroz F, Guracha TA, Haaland O, Hailu A, Hangoma P, Jamison DT, Memirie ST, Miljeteig I, Naeem AJ, Nam SL, Norheim OF, **Verguet S**, Walkins DA, Johansson KA. Protecting essential health services in low-income and middle-income countries and humanitarian settings while responding to the COVID-19 pandemic. *BMJ Global Health* 2020; 5:e003675(9 pages).
110. Lamu AN, Jbaily A, **Verguet S**, Robberstad B, Norheim OF. Is cycle network expansion cost-effective? An economic evaluation of cycling in Oslo. *BMC Public Health* 2020; 20:1869.
111. **Verguet S**, Limasalle P, Chakrabarti A, Husain A, Burbano C, Drake L, Bundy DAP. The broader economic value of school feeding programs in low- and middle-income countries: estimating the multi-sectoral returns to public health, human capital, social protection and the local economy. *Frontiers in Public Health* 2020; 8:587048.
112. **Verguet S**, Kearns P, Rees VW. Questioning the regressivity of tobacco taxes: a distributional accounting impact model of increased tobacco taxation. *Tobacco Control* 2021; 30:245-257.
113. Li X, Mukandavire C, Cucunubá ZM, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze I, Gaythorpe K, Grassly NC, Hallett TB, Jackson ML, Jean K, Karachaliou A, Klepac P, Lessler J, Li X, Moore SM, Nayagam S, Nguyen DM, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Sy S, Tam Y, Tanvir H, Minh Tran Q, Trotter CL, Truelove S, van

- Zandvoort K, **Verguet S**, Walker N, Winter A, Ferguson NM, Garske T. Estimating the health impact of vaccination against 10 pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. *Lancet* 2021; 397:398-409.
114. Memirie ST, Nigus M, **Verguet S**. Decision science and health economics for vaccine in Ethiopia: summary of available evidence. *Journal of Global Health Reports* 2021; 4:e2020076(8 pages).
 115. **Verguet S**, Hailu A, Teshome G, Johansson KA, Memirie ST, Norheim OF. Toward universal health coverage in the post-COVID-19 era. *Nature Medicine* 2021; 27:380-387.
 116. Menkir TF, Jbaily A, **Verguet S**. Incorporating equity in infectious disease modeling: a distributional impact framework of measles transmission. *Vaccine* 2021; 39(21):2894-2900.
 117. Portnoy A, Sweet S, Desalegn D, Memirie ST, Kim JJ, **Verguet S**. Health gains and financial protection from human papillomavirus (HPV) vaccination in Ethiopia: findings from a modelling study. *Health Policy and Planning* 2021; 36(6):891-899.
 118. Jamison JC, Bundy DAP, Jamison DT, Spitz J, **Verguet S**. Comparing the impact on COVID-19 mortality of self-imposed behavior change and of government regulations across 13 countries. *Health Services Research* 2021; 56:874-884.
 119. Khadka A, **Verguet S**. The economic value of changing mortality risk in low- and middle-income countries: a systematic breakdown by cause of death. *BMC Medicine* 2021; 19:156.
 120. Arsenault C, Kassa M, Yakob B, Dinsa G, **Verguet S**. Using health management information system data: case study and verification of institutional deliveries in Ethiopia. *BMJ Global Health* 2021; 6:e006216.
 121. Lofgren K, Watkins DA, Memirie ST, Salomon JA, **Verguet S**. Balancing health and financial protection in health benefit package design. *Health Economics* 2021; 30:3236-3247.
 122. Feldhaus IM, Nagpal S, **Verguet S**. Alleviating the burden of diabetes with Health Equity Funds: economic evaluation of the health and financial risk protection benefits in Cambodia. *PLoS ONE* 2021; 16(11):e0259628.
 123. **Verguet S**, Norheim OF. Estimating and comparing health and financial risk protection outcomes in economic evaluations. *Value in Health* 2022; 25(2):238-246
 124. Hendrix N, Veenstra D, Cheng M, Anderson NC, **Verguet S**. Assessing the economic value of clinical artificial intelligence: challenges and opportunities. *Value in Health* 2022; 25(3):331-339.
 125. Jbaily A, Haakenstad A, Kiros M, Riumallo-Herl C, **Verguet S**. Examining the density in out-of-pocket spending share in the estimation of catastrophic health expenditures. *European Journal of Health Economics* 2022; 23:903–912.

126. Gibbs N, Angus C, Dixon S, Parry C, Meier P, Boachie M, **Verguet S**. Equity impact of minimum unit pricing of alcohol among household health and finances among rich and poor smokers. *BMJ Global Health* 2022; 7:e007824.
127. Dhufera HT, Jbaily A, **Verguet S**, Tolla MT, Johansson KA, Memirie ST. Financial risk of road traffic trauma care in public and private hospitals in Addis Ababa, Ethiopia: a cross-sectional observational study. *Injury* 2022; 53:23-29.
128. Jbaily A, Zhou X, Liu J, Lee T-H, Kamareddine L, **Verguet S**, Dominici F. Air pollution exposure disparities across US population and income groups. *Nature* 2022; 601:228-233.
129. Memirie ST, Yigezu AL, Zewdie SA, Mirkuzie AH, Bolongaita S, **Verguet S**. Hospitalization costs for COVID-19 in Ethiopia: empirical data and analysis from Addis Ababa's largest dedicated treatment center. *PLoS ONE* 2022; 17(1):e0260930.
130. McConnell M, Mahajan M, Bauhoff S, Croke K, **Verguet S**, Castro MC, Furtado K, Mehndiratta A, Farzana M, Rashid SF, Cash R. How are health workers paid and does it matter? Conceptualizing the potential implications of modernizing health worker payments in LMICs. *BMJ Global Health* 2022; 7:e007344.
131. Hendrix N, Kwete XJ, Bolongaita S, Megiddo I, Memirie ST, Mirkuzie AH, Nonvignon J, **Verguet S**. Economic evaluations of health system strengthening activities in low- and middle-income country settings: a methodological systematic review. *BMJ Global Health* 2022; 7(3):e007392.
132. Chakrabarti A, Memirie ST, Yigletu S, Kiros M, **Verguet S**. The potential distributional health and financial benefits of increased tobacco taxes in Ethiopia: findings from a modeling study. *Social Science and Medicine–Population Health* 2022; 18:101097.
133. **Verguet S**, Bolongaita S, Morgan A, Sudfeld C, Perumal N, Yousafzai AK, Fink G. Priority setting in early childhood development: an analytical framework for economic evaluation of interventions. *BMJ Global Health* 2022; 7:e008926.
134. Chakrabarti A, **Verguet S**. Conceptualizing monetary benchmarks for health investments toward poverty reduction in low- and lower-middle-income countries. *PLoS Global Public Health* 2022; 2(6):e0000487.
135. Haakenstad A, Bukhman G, Coates M, McConnell M, **Verguet S**. Comparative health systems analysis of differences in catastrophic health expenditure associated with non-communicable versus communicable diseases among adults in six countries. *Health Policy and Planning* 2022; doi.org/10.1093/heapol/czac053.
136. Bolongaita S, Villano D, Memirie ST, Mirkuzie AH, Sato R, Comas S, Kiros M, Rumpler E, Wu S, Chang A, **Verguet S**. Modeling the relative risk of incidence and mortality of select vaccine-preventable diseases by wealth group and geographic region in Ethiopia. *PLoS Global Public Health* 2022; 2(8):e0000819.
137. **Verguet S**, Niwa M, Bolongaita S. The top and bottom longevity of nations: a retrospective analysis of the distribution of age at death across 18 countries from the OECD. *European Journal of Public Health* (in press).

Chapters in books

1. Jamison DT, Jha P, Malhotra V, **Verguet S**. The twentieth century transformation of human health: its magnitude and value. In: Lomborg B, editor. How much have global problems cost the world? - A scorecard from 1900 to 2050. Cambridge: Cambridge University Press; 2013.
2. Jha P, Nugent R, **Verguet S**, Bloom D, Hum R. Chronic disease prevention and control. In: Lomborg B, editor. Global problems, smart solutions - Costs and benefits. Cambridge: Cambridge University Press; 2013.
3. Shrimpe MG, **Verguet S**, Johansson KA, Desalegn D, Jamison DT, Kruk ME. Task-sharing or public finance for the expansion of surgical access in rural Ethiopia: an extended cost-effectiveness analysis. In: Debas HT, Donkor P, Gawande A, Jamison DT, Kruk ME, Mock, CN, eds. Disease Control Priorities. Volume 1: Essential surgery. Washington, DC: World Bank, 2015.
4. Levin CE, Sharma M, Olson Z, **Verguet S**, Shi J-F, Wang S-M, Qiao Y-L, Jamison DT, Kim J. An extended cost-effectiveness analysis of HPV vaccination to prevent cervical cancer in China. In: Gelband H, Jha P, Sankaranarayanan S, Horton S, eds. Disease Control Priorities. Volume 3: Cancer. Washington, DC: World Bank, 2015.
5. **Verguet S**, Pecenka C, Johansson KA, Memirie ST, Friberg IK, Driessen JR, Jamison DT. Health gains and financial risk protection afforded from prevention and treatment of diarrhea and pneumonia in Ethiopia. In: Black R, Temmerman M, Laxminarayan R, Walker N, eds. Disease Control Priorities. Volume 2: Reproductive, maternal, newborn and child health. Washington, DC: World Bank, 2016.
6. Chisholm D, Johansson KA, Raykar N, Megiddo I, Nigam A, Bjerkreim Strand K, Colson C, Fekadu A, **Verguet S**. Universal health coverage for mental, neurological, and substance use disorders: an extended cost-effectiveness analysis. In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Nora MEI, eds. Disease Control Priorities. Volume 4: Mental, neurological, and substance use disorders. Washington, DC: World Bank, 2016.
7. **Verguet S**, Gauvreau C, Mishra S, MacLennan M, Murphy S, Brouwer E, Nugent RA, Zhao K, Jha P, Jamison DT. The consequences of tobacco taxation on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis. In: Hu T-w, editor. Economics of tobacco control in China: from policy research to practice. Singapore: World Scientific Publishing Co, 2016.
8. **Verguet S**, Jamison DT. Selecting health benefits packages in low- and middle-income countries using the extended cost-effectiveness analysis (ECEA) methodology. In: Giedion U, Glassman A, Smith PC, editors. What's in, what's out? Designing benefits for universal health coverage. Washington, DC: Center for Global Development 2017.
9. Mock C, Smith KR, Kobusingye O, Nugent R, Abdalla S, Ahuja R, Apramian S, Bachani A, Bellis MA, Butchart A, Cantley L, Chase C, Cullen M, Dabestani N, Ebi K, Fang X, Gururaj G, Guttikunda S, Hess J, Hoe CH, Hutton G, Hyder A, Ivers R, Jamison D, Jawahar P, Keay L, Levin C, Liao J, Mackie D, Malik K,

- Meddings D, Nguyen NP, Norton R, Olson Z, Partridge I, Peden M, Pillarisetti A, Rahman F, Rosenberg M, Staples JA, **Verguet S**, Ward C, Watkins D. Injury prevention and environmental health: key messages from the volume. In: Mock CN, Smith KR, Kobusingye O, Nugent R, eds. Disease Control Priorities. Volume 7: Injury prevention and environmental health. Washington, DC: World Bank 2017.
10. Olson Z, Staples JA, Mock C, Nguyen NP, Bachani AM, Nugent R, **Verguet S**. Helmet regulation in Vietnam: impact on health, equity, and medical impoverishment. In: Mock CN, Smith KR, Kobusingye O, Nugent R, eds. Disease Control Priorities. Volume 7: Injury prevention and environmental health. Washington, DC: World Bank 2017.
 11. **Verguet S**, Nandi A, Filippi V, Bundy DP. Maternal deaths and impoverishment averted by postponing age at parity through education: an extended cost-effectiveness analysis. In: Bundy DP, de Silva N, Horton S, Jamison DT, Seddoh A, eds. Disease Control Priorities. Volume 8: Child and adolescent development. Washington, DC: World Bank 2017.
 12. Watkins DA, Jamison DT, Mills A, Atun R, Danforth K, Glassman A, Horton S, Jha P, Kruk M, Norheim OF, Qi J, Soucat A, **Verguet S**, Wilson D, Alwan A. Universal health coverage and essential packages of care. In: Jamison DT, Nugent R, Gelband H, Horton S, Jha P, Laxminarayan R, eds. Disease Control Priorities. Volume 9: Disease control priorities, improving health and reducing poverty. Washington, DC: World Bank 2017.
 13. Krakauer E, Ali Z, Arreola H, Bhadelia A, Connor S, de Lima L, Gelband H, Jamison DT, Thanh Khanh Q, Kwete X, Mpanumusingo E, Rajagopal MR, Tapela N, **Verguet S**, Knaul FM. Palliative care in response to the Global Burden of Remediable Suffering. In: Jamison DT, Nugent R, Gelband H, Horton S, Jha P, Laxminarayan R, eds. Disease Control Priorities. Volume 9: Disease control priorities, improving health and reducing poverty. Washington, DC: World Bank 2017.
 14. Ogbuaji O, Olson ZD, Yamey G, Norheim OF, **Verguet S**, Jamison DT. Annual rates of decline in child, maternal, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2015. In: Jamison DT, Nugent R, Gelband H, Horton S, Jha P, Laxminarayan R, eds. Disease Control Priorities. Volume 9: Disease control priorities, improving health and reducing poverty. Washington, DC: World Bank 2017.
 15. Watkins DA, Nugent RA, **Verguet S**. Extended cost-effectiveness analysis (ECEA) for cardiovascular disease interventions. In: Prabhakaran D, Gaziano T, Mbanya J-C, Nugent RA, Wu Y, Anand S, eds. Disease Control Priorities. Volume 5: Cardiovascular, respiratory, and related disorders. Washington, DC: World Bank 2017.
 16. **Verguet S**, Jamison DT. Health policy analysis: applications of extended cost-effectiveness analysis (ECEA) methodology in DCP3. In: Jamison DT, Nugent R, Gelband H, Horton S, Jha P, Laxminarayan R, eds. Disease Control Priorities. Volume 9: Disease control priorities, improving health and reducing poverty. Washington, DC: World Bank 2017.

17. **Verguet S**, Memirie ST, Tolla MT, Jamison DT. Extended cost-effectiveness analysis. In: Norheim OF, Emanuel EJ, Millum J, eds, Global health priority-setting: beyond cost-effectiveness. New York: Oxford University Press, 2019.
18. Jamison DT, Jamison JC, Norheim OF, **Verguet S**. Inequality in survival. In: Norheim OF, Emanuel EJ, Millum J, eds, Global health priority-setting: beyond cost-effectiveness. New York: Oxford University Press, 2019.
19. Ottersen T, Millum J, Ruger JP, **Verguet S** Johansson KA, Emanuel E, Jamison DT, Norheim OF. The future of priority setting in global health. In: Norheim OF, Emanuel EJ, Millum J, eds, Global health priority-setting: beyond cost-effectiveness. New York: Oxford University Press, 2019.